About LYFNUA
About LYFNUA®▼ (gefapixant)
LYFNUA®▼ (gefapixant)
Prescribing Information [External link]
LYFNUA is available by private prescription only and is not available via the NHS
LYFNUA is indicated in adults for the treatment of refractory and unexplained chronic cough1
This is a fictional patient
LYFNUA is thought to reduce chronic cough by targeting and inhibiting the activation of the P2X3 receptor1
LYFNUA was evaluated in two phase 3 clinical trials, including extensions up to week 521
LYFNUA is a non-narcotic with a safety profile established in two 52-week phase 3 clinical trials1,2
As a treatment indicated for refractory and unexplained chronic cough, LYFNUA helps address an unmet medical need1,2
Always refer to the full Summary of Product Characteristics before prescribing for up to-date and complete safety considerations to help minimise the risks associated with the use of LYFNUA.
Please click here for the Summary of Product Characteristics [External link]
Stay informed about the latest on LYFNUA
Click the sign up button and consent to receive promotional emails, resources and invitations to meetings
References
- LYFNUA Summary of Product Characteristics.
- Muccino DR, Green S. Pulm Pharmacol Ther. 2019;56:75-78.
Supporting documentation
LYFNUA®▼ (gefapixant)
Prescribing Information (Great Britain)
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
